A preclinical model for experimental chemotherapy of human head and neck cancer

  • Authors:
    • Konrad Sommer
    • Stefan O. Peters
    • Ian H. Robins
    • Michael Raap
    • Gunter J. Wiedemann
    • Stephan Remmert
    • Peter Sieg
    • Cordula Bittner
    • Thomas Feyerabend
  • View Affiliations

  • Published online on: June 1, 2001     https://doi.org/10.3892/ijo.18.6.1145
  • Pages: 1145-1149
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We developed a mouse model in a representative human derived head and neck cancer cell line for preclinical studies to evaluate antitumor response, tumor-free survival and host toxicity of alkylating agents, antimetabolites, platinum analogs and taxanes alone or in combination. Ninety athymic NMRI mice were inoculated with human derived oral squamous cell carcinoma cells growing on the hind paw to an average volume of 180±80 mm3. Animals were stratified according to tumor volume into 10 groups (n=6-10) and treated with ifosfamide (65 mg/kg b.w.), docetaxel (24 mg/kg b.w.), cisplatin (2 mg/kg b.w.), carboplatin (6 or 10 mg/kg b.w.), methotrexate (1 mg/kg b.w.), and fluorouracil (15 mg/kg b.w.) intravenously in single agent or combination (ifosfamide plus docetaxel or ifosfamide plus carboplatin) treatment schedules or controls. Tumor volume was measured 3 times per week for 60 days. The average tumor volume, the overall survival time and the response rates (CR, PR) of the treated animals were compared with the data obtained from untreated controls and statistically evaluated. Untreated tumors showed rapid and exponential tumor growth. Single agent therapies with ifosfamide, cisplatinum, and docetaxel lead to significant tumor regression and improved overall survival. Low dose carboplatin monotherapy induced significant tumor growth delay, but not significant tumor regression. Most impressive tumor-free survival was achieved by combination treatment with ifosfamide and docetaxel. This preclinical study demonstrates an animal model capable of differentiating various chemotherapy regimens.

Related Articles

Journal Cover

June 2001
Volume 18 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sommer K, Peters SO, Robins IH, Raap M, Wiedemann GJ, Remmert S, Sieg P, Bittner C and Feyerabend T: A preclinical model for experimental chemotherapy of human head and neck cancer. Int J Oncol 18: 1145-1149, 2001
APA
Sommer, K., Peters, S.O., Robins, I.H., Raap, M., Wiedemann, G.J., Remmert, S. ... Feyerabend, T. (2001). A preclinical model for experimental chemotherapy of human head and neck cancer. International Journal of Oncology, 18, 1145-1149. https://doi.org/10.3892/ijo.18.6.1145
MLA
Sommer, K., Peters, S. O., Robins, I. H., Raap, M., Wiedemann, G. J., Remmert, S., Sieg, P., Bittner, C., Feyerabend, T."A preclinical model for experimental chemotherapy of human head and neck cancer". International Journal of Oncology 18.6 (2001): 1145-1149.
Chicago
Sommer, K., Peters, S. O., Robins, I. H., Raap, M., Wiedemann, G. J., Remmert, S., Sieg, P., Bittner, C., Feyerabend, T."A preclinical model for experimental chemotherapy of human head and neck cancer". International Journal of Oncology 18, no. 6 (2001): 1145-1149. https://doi.org/10.3892/ijo.18.6.1145